Cell Culture Engineering XVIII

An ECI Conference Series

April 23-28, 2023
Grand Fiesta Americans Coral Beach Hotel
Cancun, Mexico

Poster Size: no larger than 1 m wide and 1.5 m long

Invitation only conference

This conference is by invitation only. Invitees will be sent an email with a link to the conference registration page. To be considered for an invitation, please complete the Request for Next Mailing online application. Note: If you have previously completed the online Request for Next Mailing, you have already been added to the list of applicants.

Attendance at this conference is restricted to those fully* vaccinated against Covid-19.

Your registration will not be considered complete until your proof of vaccination is uploaded via the registration portal and verified by ECI staff. Acceptable proof includes copies of a U.S. CDC vaccination card or a certificate/document (listing your full name as it appears on your government issued ID) issued by the relevant health agency in your country of residence along with a government issued photo ID, such as a driver’s license or passport. Please do not upload a QR code as proof because ECI does not have a compatible QR code reader due to region difference. If you have questions about these requirements, please email Kathy@engconfintl.org

* Two doses of an FDA or WHO authorized Covid-19 vaccine plus appropriate boosters, received at least 14 days prior to the conference OR one dose of an FDA or WHO authorized single dose Covid-19 vaccine, received at least 14 days prior to the conference.

We are all in this together. Thank you for being part of our community and following these policies. We look forward to see you in person very soon.

Click for CDC information on Covid vaccines.

Click for WHO information on Covid vaccines.

About This Conference

Since its beginning in 1988, the Cell Culture Engineering Conference series has been a very influential forum for leaders and experts from academic, regulatory, and industrial backgrounds to convene and discuss cell culture and related advancements that impact a growing spectrum of modalities including recombinant biologics, cell and gene therapies, and viral vaccines. Rapid advances in the field over the last few years coupled with vaccine and therapeutic development experiences from the pandemic have resulted in innovation and novel learnings that are ideal for stimulative discussion and debate. 

Exceptional effort had been put into the CCE XVII Tucson conference that, unfortunately, had to be cancelled and we thank the chairs, Gargi Maheshwari, Jamey Young, Tim Charlebois and other community members who had contributed towards constructing that concept. We will build on that excellent foundation and design a compelling program for CCE XVIII which we intend to have in-person in Cancun in April 2023. CCE XVIII welcomes invited participants across all walks of the practice of cell culture and related technologies and will provide a platform for exchange of cutting-edge scientific and technological advances and related discussions and debates that can help share the future of the discipline.

It was May 2018 when our community was last together at the Tampa CCE XVI conference and we are very excited to host CCE XVIII in April 2023. We look forward to working with some of you on the planning of the conference and to interacting with all of you at the conference.

Laura, Tongtong, and Chetan

Conference Organization

Conference Chairs

Laura A. Palomares, Instituto de Biotecnología, UNAM
Chetan Goudar, Amgen
Tongtong Wang, Genentech

CCE Steering Committee

Dana Andersen (Denali Therapeutics, USA)
John Aunins
(Janis Biologics, USA)
Mike Betenbaugh (Johns Hopkins University, USA)
Barry Buckland (BiologicB LLC, USA)
Jeff Chalmers (The Ohio State University, USA)
Tim Charlebois (NIIMBL, USA)
Matt Croughan (Claymore Bio LLC, USA)
Chetan Goudar (Amgen, USA)
Peter Gray (University of Queensland, Australia)
Sarah Harcum (Clemson University, USA)
Wei-Shou Hu (University of Minnesota, USA)
Beth Junker (Bioprocess Advantage, USA)
Amine Kamen (McGill University, Canada)
Robert Kiss (UPSIDE Foods, USA)
Konstantin Konstantinov (Codiak Biosciences, USA)
Lynne Krummen (Vir, USA)
Kelvin Lee (University of Delaware, USA)
Mark Leonard (Allogen Therapeutics, USA)
Gargi Maheshwari (BMS, USA)
Laura Palomares (Instituto de Biotecnología, UNAM, Mexico)
Jamie Piret (University of British Columbia, Canada)
Octavio Ramirez (Instituto de Biotecnología UNAM, Mexico)
Anne Skaja Robinson (Carnegie Mellon University, USA)
Gene Schaefer (NIIMBL, USA)
Raghavan Venkat (AstraZeneca, USA)
Tongtong Wang (Roche, USA)
Jamey Young (Vanderbilt University, USA)
Weichang Zhou (WuXi Biologics, China)

Conference Program

Early Careers Pre-Conference (ECP)

Keynote Speakers

Conference Sessions

Session 1: Multispecific Modalities: Commercialization Successes and Future Trends

Session Chairs: Inn Yuk (Genentech) and Christopher Howard (The University of Queensland)

Multispecific modalities have emerged at the forefront of next-generation therapeutics by creating new possibilities for drug targeting. Unlike conventional modalities with a single drug-target interface, multispecific modalities engage multiple (two or more) entities to form multiple drug-target interfaces. In addition to providing enhanced targeting and therapeutic impact, these novel formats can also be engineered to minimize toxicity and maximize binding, functionality, and efficacy. While multispecific modalities have revolutionized the paradigm for drug targeting and delivered new treatments for patients, the inherent complexities of these modalities have also introduced new challenges to multiple aspects of manufacturability. This session will showcase successes in the commercialization of multispecific modalities and share lessons learned in overcoming the manufacturability challenges associated with these complex therapeutics. This session will also discuss future trends and highlight advances in different technical aspects of developing commercializable multispecific modalities, including the following: (i) protein engineering approaches to create and optimize novel formats; (ii) cell line engineering strategies to enhance expression; and (iii) bioprocess design considerations to develop scalable manufacturing processes with high productivity and consistent product quality.

Session 2: Cell Line Development: Current State and Future Directions

Session chairs: Zhimei Du (Landmark Bio), Mark Smales (University of Kent) and Jamey Young (Vanderbilt University)

Advances in molecular biology and genome editing tools have expedited cell line development for the production of high-quality biologics. These technologies are complemented by increased genome sequence availability, better understanding of the control of gene expression in industrial host-vector systems, and progress in high-throughput screening strategies. As a result of these rapidly evolving capabilities, the design and application of cell engineering strategies has never been better positioned, nor the opportunities and potential more exciting, to deliver new engineered host cells with enhanced capacity to produce high value and quality biologics. This session focuses on all these aspects that underpin cell engineering, covering novel approaches and/or technologies to deliver engineered and/or selected cells for establishing recombinant cell lines with improved performance. Topics may include direct host cell engineering (e.g., genome editing, site-specific integration or synthetic biology approaches to redesign the cell, manipulation of non-coding RNAs), vector engineering (e.g., vector design and components, inducible systems, codon optimization, control of transcription and translation), novel methods for recombinant clone generation, selection and screening, and novel methods for ensuring, predicting and characterizing clone stability and determining/extending the limit of in vitro cell age for production.

Session 3: Controlling Complexity by Systems and Synthetic Biology for Improved Biologics Production

Session Chairs:  Bhanu Chandra Mulukutla (Pfizer) and Nicole Borth (BOKU Vienna)

Since 1987, mammalian host systems have evolved to be the workhorses of biologics production despite their intertwined complex physiological functions making their control in cell culture processes challenging. Systems biology, which employs omics technologies integrated with mathematical modeling, provides a systematic way to study and understand the complexity in a holistic manner.  Synthetic biology complements this by providing advanced genetic engineering tools and circuits to modulate such physiological functions.  Over the last decade, systems biology approaches were employed by the bioprocessing community in an exploratory fashion towards attaining deeper understanding of routinely used cell lines and cell culture processes.  More recently, the combination of systems biology and synthetic biology is being applied towards achieving tangible solutions for specific cell culture process related questions by enhancing and/or fine tuning relevant cellular physiological functions, in particular those that require control of multiple genes or entire pathway/function. This session will mainly focus on such studies that demonstrate tangible outcomes to modulate cell growth, protein or viral vector/particle production, product quality or any other aspects of biologics production. In addition, this session will also focus on studies contriving novel solutions in the form of application of bioinformatics tools or digital twins/mathematical models to address challenges with handling, analysis, and interpretation of big data, typically generated as part of systems and synthetic biology efforts.

Session 4: Advances in Cell Culture Control and Analysis

Session chairs: Marcella Yu (Sutro Biopharma) and Sarika Mehra (IIT Bombay)

Understanding of the relationship between cell culture process control and desirable product quality attributes in protein therapeutics has matured significantly over the past several years.  Sophistication in control strategies, analytical outputs and models that link the two has advanced both at the laboratory scale as well as demonstration of implementation and benefit at GMP scale.  This session will capture advances in the area of process understanding and process control with the focus on achieving desired product quality attributes.  Additionally, topics will include state-of-the-art Process Analytical Technology (PAT) and tools that allow feedback control of the upstream processes, as well as work that demonstrates implementation of these PAT tools in a GMP facility.   Genome-scale in silico modeling to predict and modulate product quality responses (including Critical Quality Attributes) and smart integration of artificial intelligence to close the gaps between predicted models and experimental data will also be covered.  Additionally, process modeling and tools to analyze big data such as machine learning and artificial intelligence approaches toward heighten level of process understanding and process control will be of interest.  Finally, any novel approaches to cell culture process control strategies will also be considered for this session.

Session 5: Engineering Technologies for Cell-based Therapies (CCE for Cell-based Therapies)

Session chairs: John Moscariello (BMS) and Krish Roy (Georgia Tech)

Cell-based therapies have transformative potential for treating complex diseases, and are rapidly becoming an important product area for the biopharmaceutical industry. However, reproducible and scalable manufacturing of therapeutic cells, with high and consistent quality at a reasonable cost has been challenging—underscoring the need for significant innovations. This session will focus on engineering tools and technologies for reproducible manufacturing of therapeutic cells, including licensed cell types like T cells, and emerging cell types, e.g. NK cells, B cells, Macrophages, HSCs, MSCs, and iPSCs or iPSC-derived cells. Specifically, abstracts related to the tools and methods related to advanced cell engineering and universal/allogeneic cell production, improved bioprocessing to reduce culture time and cost or to selectively expand the most safe and potent cell subsets, deep cell characterization including multi-omics approaches, in-line process and product monitoring, feedback and process control, data analytics for critical quality attribute (CQA) and critical process parameter (CPP) identification, and process and supply chain modeling, are welcome.

Session 6: Production of Viral Vectors and Other Emerging Therapeutic Modalities

Session chairs: Scott Estes (Codiak Bio) and Paula M. Alves (IBET & ITQB NOVA)

This session will highlight recent bioprocessing progress beyond the well-established realm of protein therapeutics, emphasizing production of viral vectors, vaccines and other emerging therapeutic modalities. The present surge of clinical trials that rely on viral vectors for gene delivery indicates that gene therapy is becoming a viable therapeutic modality and may soon provide cures for a broad range of human diseases. However, significant strides are needed in vector production process efficiencies and industrialization to deliver COGs for small orphan indications that support reimbursement rates acceptable to both sponsors and payers. Progress on this front is also needed for indications with larger patient populations and/or large doses to meet the demand for these therapeutics. Second with the world still grappling with the global coronavirus pandemic, efforts focused on technology innovations in the vaccine space have become of great interest. While the development and implementation of mRNA based vaccines has been extraordinarily successful in blunting the severity of the outbreak, there is still the need for next generation vaccines that are more broadly protective and have longer effectiveness. This session encourages submission of abstracts describing innovative work enhancing viral vector productivity and robustness through vector engineering, host cell line optimization and/or process development as well as abstracts describing innovations in the production of next generation vaccines, oncolytic viruses, exosomes and other non-viral therapeutic delivery systems.

Session 7: Advances in Integrated Continuous Bioprocessing

Session chairs: Massimo Morbidelli (Politecnico di Milano) and Jason Walther (Sanofi)

Progress continues to be made on the application of continuous principles in biomanufacturing. Advances both on technical and financial dimensions have been made and there is improved understanding of capital deployment, speed, and productivity targets necessary to make continuous processes an attractive commercial manufacturing approach. Additionally, multiple sponsors have had positive interactions with regulatory agencies who have expressed support for new technologies. We are also starting to accumulate GMP experience around unit operations leading up to drug substance manufacturing, including the deployment of PAT and process control strategies to enable reliable operation. The intent of this session will be to highlight the state-of-the-art in integrated continuous bioprocessing for drug substance production. The latest advancements in cell culture and purification processes with an emphasis on integration will be included as will topics related to PAT, process control and digital twins. Topics related to process economics that can direct strategies for the design, construction, and licensure of manufacturing plants will also be discussed.

Call for Abstracts

Dear colleagues in the CCE community,

ECI and the CCE-XVIII organizing committee are excited to host next year’s meeting in person in Cancun and this is a reminder to submit abstracts for oral presentations by September 30th and October 15 for poster presentations. To enable conference participants to share their latest cell culture advances, abstract submissions from CCE-XVII will not be carried over and we request potential participants to make de novo oral and poster abstract submissions to CCE-XVIII using the link in this email.

Laura, Chetan, and Tongtong

Abstract Submission

Detailed session descriptions are available above.  Please use these descriptions to pre-select up to three sessions where you believe your work fits best.

Abstracts (one page maximum) that include specific results and conclusions to allow a scientific assessment of the proposed oral presentation are invited. 

Abstracts must be submitted electronically and prepared according to this template:  docx or doc.

Oral abstract submission deadline: September 30, 2022
Poster abstract submission deadline: October 15, 2022

Abstracts of all presentations will be made available to conference participants prior to the start of the conference.

Awards will be presented to the top three student posters. 



Anurag Khetan (Bristol-Myers Squibb, USA)
Margarida Serra (iBET, Portugal)

Martin Sinacore Awardees

2021 Martin Sinacore Young Investigator Award Co-Winners

Pooja Jambunathan

Pooja Jambunathan works in Biologics Process Development and Commercialization group at Merck, where she supports commercialization and lifecycle activities for biologics. She joined Merck in 2017 after completing her Ph.D. in Chemical Engineering at the University of Minnesota. Since joining Merck, she has led a geographically diverse team to develop a global scale-down model across multiple small-scale labs to troubleshoot manufacturing investigations and to mitigate supply chain risks thus ensuring uninterrupted supply of the blockbuster immune-oncology drug Keytruda to patients worldwide. Her role as the upstream lead for technology transfer of processes to external contract manufacturing organizations (CMOs) and internal manufacturing sites has helped to increase process understanding and robustness for existing and future commercial biologics. 

Pooja has a strong understanding of global healthcare issues in emerging countries and a strong technical knowledge for global drug development considering geographic and organizational diversities. She has made positive impact on a global level working with NGO partners to improve access and affordability of essential medicines in Tanzania. During this assignment, her leadership and dedication to global health led to capacity gains and improved access to healthcare for the local communities in Tanzania.

As an Equity, Diversity, and Inclusion (ED&I) champion, Pooja has led teams both at Merck and in graduate school aimed at making the workplace a connected and diverse community where individuals can bring their full selves to work. As a Women’s group coordinator in graduate school, she organized outreach programs at local schools to encourage young girls to join STEM field. Currently she leads a cross-departmental team that focuses on addressing workplace diversity through participation in ED&I conferences and raising ED&I awareness through facilitated workshops.

Madhuresh Sumit

Madhuresh Sumit joined the Upstream Process Development group at Pfizer in 2016 after completion of a Chemical Engineering Masters and a Biophysics PhD at the University of Michigan – Ann Arbor. In his PhD work, Madhuresh employed mathematical modeling and cell culture experimentation to dissect temporal dynamics and information processing mechanisms in a mammalian cell signaling pathway.

At Pfizer, Madhuresh worked in collaboration with MIT on Post-translational Modification (PTM) project that resulted in significant advancement in precision control of N-glycosylation in CHO cell culture using systems and synthetic biology approaches. Madhuresh developed systems biology tools and mathematical models for accurate prediction and pro-active control of temporal variations in N-glycans in the recombinant proteins produced in CHO cells during a fed-batch process.Furthermore, has contributed significantly to the in-silico modeling and big data analytics in upstream bioprocessing in various industry consortia. In addition to engaging in research and technical development over his ~4-year industrial career, Madhuresh has played a key-role in the advancement of multiple innovative molecules in Pfizer’s early-stage pipeline.

Cell Culture Engineering Awardee

2021 Cell Culture Engineering Award Winner 

Manuel Carrondo 

Professor of Chemical and Biochemical Engineering, Universidade Nova de Lisboa 

Founder of iBET – Instituto de Biologia Experimental e Tecnológica and GenIBET  Biopharmaceuticals 

Manuel Carrondo’s over thirty years of service to cell culture is due to strong partners and supporters of iBET – Instituto de Biologia Experimental e Tecnológica, which he founded in Oeiras, near Lisboa in 1989 (www.ibet.pt). 

Daniel I.C.Wang gave Manuel the entrance to the CCE “boiling pot” he directed at MIT’s BPEC (visiting in1984 and 1988) and its outstanding network. Joachim Klein, director of Geselschaft für Biotechnology Forschung, Braunschweig, GBF (now Helmholtz) (visiting 1989) opened the door to the European biotechnology core. Both kept membership of  iBET´s Scientific Advisory Board for almost twenty years, proposing challenging ideas and broadening  iBET’s operation. John Aunins, Danny’s ex-Ph.D. student and iBET champion, exposed iBET to Merck &  Co, where Barry Buckland was building the “industrial” CCE powerhouse, while Hansjörg Hauser, molecular  cell and virus geneticist at GBF contributed the “bio” to the “technology” at iBET. Over the last decade, Clive  Wood (BI) became a key supporter for Translational Medicine inroads at iBET 

Having been able to motivate top students into Ph.D.’s., Manuel could afford “risk taking” in process  development – from perfusing and purifying retroviral vectors (late 90’s) to expanding and differentiating  hESC (mid 2000’s), always bridging USA and EU partnerships, as CCE was absent in Portugal. José Luís  Moreira ( 2014), first CCE Ph.D. student and enthusiastic “icebreaker” and Paula Alves, iBET’s CEO since  2012, deserve special mention. 

In 2006, Manuel founded GenIBET Biopharmaceuticals (www.genibet.com),a spin-off to produce proteins,  cells and viruses for phase I/II clinical trials. Joerg Reinhardt, then COO at Novartis, committed Siena  vaccine team to be GenIBET’s launching partner. The scientific, technological and personal trust the  iBET/GenIBET team built with very knowledgeable partner companies made the risk pay for various  oncolytic viruses or the first and following mRNA lots for Moderna (2015-2018) as well as Seres C. difficile  microbiome product (2016-ongoing). 

Process development areas impacted by Manuel include: 

Monoclonal antibodies: (from 1990) effects of culture systems and hydrodynamics, cell lines, cell  aggregation and substrate metabolism on product quality including glycosylation profile. 

Viruses: (from 1994) as competition in Mabs became too strong for a small lab, iBET transitioned to viruses,  applying them for candidate vaccines and gene therapy. Adeno-, baculo-, retro-, lenti-, and adeno  associated viruses have been targeted for process development, both up- and downstream, continuous  process integration being a current target. 

The baculovirus – insect cell platform has also been extensively developed for production of proteins and  viral like particles (VLPs).

Cells as tools for research and Cell Therapy: (from 1996) Neuron and astrocyte aggregates were perfused  as 3D cell culture systems for in vivo NMR studies. Such assemblies became well established at iBET which now also covers, eg., liver, heart or complex co-cultures of primary and/or stem and cancer cell 3D  models, completed with immune cells. After MSCs and iPSCs differentiation and expansion, processes for  cell therapy were made more robust, including use of continuous operations in both up – and downstream,  facilitating process integration and thus sterile operation. 

Mentorship and service: Attracting, training and, whenever possible, maintaining highly qualified and  committed scientists at iBET has been a key goal. The 37 Ph.D. students, plus masters and postdocs,  made Manuel’s career shine, co-wrote 250 papers and contributed to a globally well-known and trusted  iBET! Manuel has been strongly committed to the European Society of Animal Cell Technology (ESACT)  since 1995 and various Engineering Conference International (ECI) biotechnological series. 

This prestigious award recognizes outstanding contributions to the field of Cell Culture and is given bi annually at the Cell Culture Engineering conference. Former recipients: Wei-Shou Hu (2002), Eleftherios T.  Papoutsakis (2004), W. Robert Arathoon (2006), Martin Fussenegger (2008), Michael J. Betenbaugh  (2010), James M. Piret (2012), Jeffrey J. Chalmers (2014), Konstantin B. Konstantinov (2016) and William  Miller (2018).

Venue Information

Grand Fiesta Americana Coral Beach Cancun

Located on Cancun’s most secluded stretch of white sand beach, the Grand Fiesta Americana Coral Beach Cancun offers 602 all-suite ocean front accommodations, each with a private terrace facing the turquoise waters of the Caribbean and lagoon-like pool. 

Grand Fiesta Americana Coral Beach Pool

The resort is all-inclusive and is perfect for the whole family to enjoy as there are special activities for children aged 3-12 in the CoralKidZ Club, a 40,000 square foot innovative and interactive “high-tech playground” that features an array of indoor and outdoor activities. The Coral Beach Gem Spa offers innovative treatments. There is a world-class fitness center overlooking the Caribbean Sea complimentary marina activities such as kayaks, paddleboards, and snorkel gear. 

Grand Fiesta Americana Coral Beach Room

The resorts sports a large meandering lagoon-like swimming pool surrounded by palms and a tropical palapa-roofed swim-up bar.  A private secluded stretch of white-sand offers plenty of chairs and umbrellas for guests.  Luxury daybeds and beach cabanas can be reserved for an extra fee. A perfect blend of serenity and activity, the resort is steps away from Cancun’s vibrant nightlife, entertainment and shopping. For further hotel information, please check www.coralbeachcancunresort.com.

Conference technical sessions will take place in the hotel’s Convention Center.

Among the can’t miss activities near the hotel are:

Underwater Museum of Art
  • Underwater Museum of Art (MUSA)  MUSA, the Underwater Museum of Art, is located in the National Marine Park of Cancun and Isla Mujeres. It has more than 500 sculptures installed on the seabed distributed in three galleries: Manchones Gallery, in Isla Mujeres where the sculptures are located 8 meters. (26 ft.) Deep; Punta Nizuc Gallery and Punta Sam Gallery, both in Cancun, with sculptures at a depth of 4 meters. (13 ft.).
Mercado 28
  • Mercado 28   Located in the center of the city, Market 28 is a true icon of the city of Cancun. Here you can find an immense amount of Mexican souvenirs and handicrafts, also has typical food restaurants with a very good atmosphere.
Palapas Park
  • Palapas Park  If you’re looking to spend a day as a Cancunense, you definitely should go to this place. Located in the heart of the city, just a few blocks from Mercado 28, you can eat Mexican snacks, buy a snow cone to relieve heat, buy hippie crafts and watch a public show, cultural show or musical groups. Be sure to try the delicious marquesitas, a kind of rolled cream that is usually filled with ball cheese. A typical appetizer of the region.

The Cancun Area

Cancún is Mexico’s showcase resort destination and is recognized worldwide for its spectacular beaches of fine white sand, fascinating turquoise blue sea and unparalleled weather, as well as excellent air and land connectivity, and a first-class hotel infrastructure that places it as one of the best destinations tourist in the world thanks to everything it offers to its visitors: Outdoor activities, adventure tourism, archeological sites, Mayan culture and history, a variety of gastronomic experiences, spectacular shopping centers, and seductive entertainment offers.

Mayan Ruins at Chichén Itzá

Cancún makes a convenient base for exploring other parts of the Yucatán such as the famous must-see Mayan Ruins at Chichén Itzá (a UNESCO World-Heritage Site) and Tulum. The ruins of Chichén Itzá, the remains of a once-great Mayan city and one of the world’s best-known archeological sites, are about two hours away.  About 90 minutes south of downtown Cancún are the Tulum ruins, dramatically situated on a cliff overlooking the Caribbean. 

Riviera Maya, Tulum

The sixty-mile stretch of Quintana Roo coastline from Puerto Morelos to the town of Tulum is known as the Riviera Maya.  It is a rapidly growing region of nature-oriented attractions where visitors can snorkel and dive in cenotes (freshwater sink-holes), view a rich diversity of wildlife and explore beautiful beaches. 

Cenote, Tulum

The sport fishing is rewarding, and an offshore coral reef guarantees superb diving and snorkeling.  Birdwatching on Isla Contoy is a good activity to explore Cancun’s wildlife as are the eco-parks like Xcaret. 

Cancún International Airport is on the mainland, about 16 kilometers southwest of downtown Ciudad Cancún and about 10 kilometers from the southern end of Cancún Island.  The airport is modern and clearly marked with bilingual signs for arrivals, departures, gates, immigration and restrooms.


Rio Secreto

The region’s most unique natural treasure! Dare to live a fantastic experience in one of the most incredible locations in the Riviera Maya. Enter this natural museum filled with a kaleidoscope of speleothems and walk an easy 600m route amidst the thousands of stalactites and stalagmites found in this protected natural reserve. You will be greeted by our highly trained guides and equipped like a professional dive master. You will put on a wetsuit, helmet with a special lamp and wet shoes. Learn and marvel in this ancient, magical subterranean world that until now has remained unexplored for millions of years.

To operate this tour a minimum of 6 people is required.

CLICK HERE to make reservations for the Rio Secreto Tour.

Tulum Express

Find the Mayan mystic in our cultural tour of Tulum, visiting the most fascinating ruins built along the ocean side. The only known Mayan City built alongside the setting sun and is magnificently situated high atop a cliff overlooking the crystal-blue Caribbean Sea and its surrounding jungle.

Minimum for this tour: 40 people

CLICK HERE to make reservations for the Tulum Express Tour.

Chichen Itza

One of the New 7 World Wonders, Chichen Itza is located 200 km west of Cancun, 2.15 hrs. by road and is the most visited archaeological site in the peninsula of Yucatán, due to its extraordinary architecture, beauty and its geographical location.

The Castle or Pyramid of Kukulcan is the most impressive temple in Chichen Itza renowned for the number of tombs found there and its endless 91 steps, as well as the impeccable architecture that stands out by a stone feathered serpent.

The Ball Court has a cosmic meaning, with its warlike symbols and almost perfect acoustics it is one of the oldest constructions in the zone.

To operate this tour a minimum of 6 people is required.

CLICK HERE to make reservations for the Tulum Express Tour.

Jungle Tour

Drive your own boat through the mangroves to explore the coral reefs. The Guide will guide you through the lagoon’s mangroves for about 45 minutes (each way), while you enjoy the experience of the wonders of Cancun’s jungle and the exotic wildlife. Upon arrival to the reef, you will have 40 minutes for snorkeling at the world’s second-largest barrier reef. All the tour is approximately 2 1/2 hrs.

To operate this tour a minimum of 6 people is required.

CLICK HERE to make reservations for the Jungle Tour.


Transportation from Cancun airport/Grand Fiesta Americana Coral Beach Cancun – All Inclusive Hotel or back to Cancun airport Price valid from Cancun airport to Fiesta Americana Coral Beach Cancun OR any other resort or location in Cancun hotel zone.

Maximum capacity Private van: 8 passengers

  • Deluxe vehicles with air-conditioning
  • Private transportation, group participants only
  • Meet and greet at the International Airport by GIM uniformed bilingual staff
  • Complete assistance with lost luggage from the airline
  • Coordination of all luggage handling between airport and hotel
  • Printed signs with the name and logo of the program at the airport
  • Departure notice information forms per person given directly to the client
  • GIM Escorts and Supervisors at the Airport

NOTE: Gratuities to driver and luggage handling is at your discretion


Ground transportation will be provided between April 20 – May 2, 2023.
Anyone traveling outside of these dates will need to pay the rate of $65.00 USD + 16% tax one way. Payment can be done via PayPal.

Cancellations must be made 72 hours after booking services contracted.

Reservations must be made no later than Friday, April 14, 2023.

Email: jloria@gimdmc.com
After this date any space is subject to availability.

Conference Fees and Registration

Conference Fees

All conference fees are inclusive. They include registration, accommodations (nights of Sunday April 23, Monday April 24, Tuesday April 25, Wednesday April 26, and Thursday April 27 with check-out on April 28), all meals, taxes, roundtrip airport transportation and gratuities from lunch on Sunday through breakfast on Friday. Incidental fees (telephone calls, faxes, spa, laundry, minibar etc.) are billed to your personal account by the hotel.

All participants (including members of the organizing committee and invited speakers) are required to register.

The conference fees are:

Participant (single occupancy, not bringing a guest) US $3,950.00
Participant (double occupancy – sharing a room with another participant (booked separately) OR bringing a guest, additional fee** (see below))
If you do not have a roommate, we will try our best to pair you up with someone of the same gender. If we cannot find you a roommate, we will change your registration to the Single Occupancy rate and notify you of the extra fees.
US $3,275.00
Bona fide Graduate Student (double occupancy – sharing a room with another student / participant) (Those in this category must upload proof of current status during registration – copy of current Student ID or a letter from your University confirming your student status.)
If you do not have a roommate, we will try our best to pair you up with someone of the same gender. If we cannot find you a roommate, we will change your registration to the Single Occupancy rate and notify you of the extra fees.
US $2,655.00
**Fees for Guest/accompanying person sharing bedroom with a participant. (Includes all conference included meals)
Guests must register and pay the guest fee.

If you plan to bring children to the conference, please contact Kathy Chan for pricing.
US $1,680.00

Early Careers Pre-Conference (ECP) Registration Fee

Single Occupancynot sharing with participant or guestUS $595.00
Double Occupancy – sharing with a participant or guest.
If you do not have a roommate, we will try our best to pair you up with someone of the same gender. If we cannot find you a roommate, we will change your registration to the Single Occupancy rate and notify you of the extra fees.
US $460.00

Conference Registration

You will need a login name and password to register for ECI conferences through our online system. If you have been a recent participant at an ECI conference or have submitted an online application or request for information about an ECI Conference or submitted an abstract, you may already have an account with us. If you know your login information, please use it.

Invitees – You already have a login and password with us.  Please click here to retrieve your password (you will need to know your username); please click here and enter your e-mail address to retrieve your username if you do not have it.  Please do not create a new account to register because you will not have access to the registration site. If you have any questions or experience any difficulties, please email Kathy Chan.

Pre / Post Form

If you are arriving early or staying after the conference and wish to extend your stay in the conference hotel, please download and complete the Pre/Post Conference Reservation form posted below and send it directly to the conference hotel. ECI does not guarantee or pay for rooms reserved before or after the conference – you must reserve extra nights directly with the hotel and you are responsible for paying the hotel directly for any extra nights.


Wuxi Biologics
Eli Lilly
Novo Nordisk

Sponsor Information

Package B: $3,500 

  • Company recognized on sponsor list in program
  • Company logo displayed on screen between sessions 

Package C: $5,000 

  • Company recognized on sponsor list in program 
  • Company logo displayed on screen between sessions – ½ page ad in pdf program 

Package D: $7,500 

  • Company recognized on sponsor list in program 
  • Company logo displayed on screen between sessions – ½ page ad in pdf program 
  • Company logo and link on Conference web site 
  • Poster session sponsorship 

Package E: $10,000 

  • Company recognized on sponsor list in program 
  • Company logo displayed on screen between sessions – Full page ad in pdf program 
  • Company logo and link on conference website 
  • Workshop sponsorship including brief oral introduction 

Package F: $15,000 

  • Company recognized on sponsor list in program 
  • Company logo displayed on screen between sessions – Full page ad in pdf program 
  • Company logo and link on conference website 
  • Scientific session sponsorship including brief oral introduction 

Package G: $20,000 or above 

  • Company recognized on sponsor list in program 
  • Company logo displayed on screen between sessions – Full page ad in pdf program 
  • Company logo and link on conference website 
  • Scientific session sponsorship including brief oral introduction – Sponsorship of banquet 

For additional information or questions, please contact: 

Kevin M. Korpics Associate Director, Engineering Conferences International Kevin@engconfintl.org

General Information about ECI

Engineering Conferences International (ECI) is a not-for-profit, global engineering conferences program, originally established in 1962 that provides opportunities for the exploration of problems and issues of concern to engineers and scientists from many disciplines.

The format of the conference provides morning and late afternoon or evening sessions in which major presentations are made. Poster sessions will be scheduled for evening discussion as well. Available time is included during the afternoons for ad hoc meetings, informal discussions, and/or recreation. This format is designed to enhance rapport among participants and promote dialogue on the development of the meeting. We believe the conferences have been instrumental in generating ideas and disseminating information to a greater extent than is possible through more conventional forums.

All participants are expected both to attend the entire conference and to contribute actively to the discussions. The recording/photographing of lectures and presentations is forbidden. As ECI conferences take place in an informal atmosphere, casual clothing is the usual attire.

Smoking is prohibited at ECI conferences and conference functions.